Doina Ganea
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Immunotherapy and Immune Responses, Immune Response and Inflammation, Chemokine receptors and signaling, Cancer, Stress, Anesthesia, and Immune Response
Most-Cited Works
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,270 cited
- → The Significance of Vasoactive Intestinal Peptide in Immunomodulation(2004)408 cited
- → Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer(2017)376 cited
- → The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23→IL-17 Axis(2007)279 cited
- Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.(1999)
- → Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Enhance IL-10 Production by Murine Macrophages: In Vitro and In Vivo Studies(1999)197 cited
- → Cecal Ligation Puncture Procedure(2011)193 cited
- → Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6(1999)181 cited
- → Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions(2011)181 cited
- → Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun(1998)181 cited